SFDA Approves Registration of ‘Iqirvo’ for Treatment of Primary Biliary Cholangitis
Riyadh: The Saudi Food and Drug Authority (SFDA) has approved the registration of Iqirvo (Elafibranor) for the treatment of adults with primary biliary cholangitis (PBC) who have had an inadequate response to ursodeoxycholic acid (UDCA) or are unable …